Clinical trials: Mass Drug Administration
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Trachoma, Chlamydia
Trachoma Amelioration in Northern Amhara (TANA)
The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin.
- Trial name
- TANA (NCT00322972)
- Testing
- Mass treatment with oral azithromycin to an entire community
- Where
- Ethiopia
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Sarcopenia
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.
- Trial name
- NCT02468674
- Testing
- bimagrumab
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Scabies, Yaws
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
This is an open-label prospective community intervention trial to assess the impact of community mass treatment with azithromycin for yaws and ivermectin for scabies, on non-yaws bacterial skin infections.
- Conditions
- Scabies, Yaws, Impetigo
- Trial name
- AIM-Skin (NCT02775617)
- Testing
- Ivermectin, Azithromycin, Permethrin
- Where
- Solomon Islands
- Volunteers
- 1,291 people
- Sponsor
- London School of Hygiene and Tropical Medicine